Sending Office: Honorable Sanford D. Bishop, Jr.
Sent By:

Prostate Cancer deaths are on the rise!


Please help us continue needed Prostate Cancer research


DEADLINE: Friday, March 6th


Dear Colleague:


Please join us in writing the House Appropriations Committee to express your support for the Prostate Cancer Research Program (PCRP) within the Department of Defense (DoD).  Prostate cancer is the most common cancer diagnosed in men and is the second leading
cause of cancer deaths among men. One in nine men will be diagnosed in their lifetimes, and 3.1 million men are living with a prostate cancer diagnosis today. 


An estimated over 190,000 men will be diagnosed with prostate cancer in 2020.  But what is more disturbing is more than 33,000 men are expected to die in 2020 from prostate cancer – an increase of more than 2,000 deaths than in 2019 and over 7,000 more deaths
than in 2017!


In the African-American population the numbers are even more grim.  African-American men are 74 percent more likely to develop prostate cancer than Caucasian men and twice as likely to die.


We can stop these trends with the help of targeted research.


The attached letter to the Appropriations Committee requests $110 million for the PCRP in Fiscal Year (FY) 2021, which represents level funding compared to FY2020.


We appreciate your support in this vital effort to save men’s lives and support important scientific breakthroughs. Please contact Jonathan Halpern in Rep. Sanford Bishop’s office at or Deena Tauster in Rep. Peter King’s office
at by Friday, March 6th for more information or to sign-on.







______________________________                                    ______________________________

Representative Sanford D. Bishop, Jr.                                    Representative Peter T. King





March 16, 2019


The Honorable Peter Visclosky                                 The Honorable Ken Calvert

Chairman                                                                    Ranking Member

Subcommittee on Defense                                       Subcommittee on Defense

House Appropriations Committee                             House Appropriations Committee

H-405, The Capitol                                                     1016 Longworth House Office Building

Washington, DC  20515                                              Washington, DC  20515


Dear Chairman Visclosky and Ranking Member Calvert:


This year, over 190,000 men will be diagnosed with prostate cancer, and it is estimated that more than 33,000 men will die from this disease. As you consider the Fiscal Year (FY) 2021 Defense Appropriations Act, we respectfully request that the Committee
appropriate $110 million to the Department of Defense’s (DOD’s) Prostate Cancer Research Program (PCRP).


After more than two decades of decreasing prostate cancer rates, prostate cancer deaths are now on the rise. When caught early, prostate cancer has a nearly one hundred percent five-year survival rate. When the disease has metastasized, the survival rate
drops to 30 percent. It is estimated that 2,000 more men will die this year than in 2019 of prostate cancer.  And that number reflects an increase of 7,000 more deaths when compared to 2017.  Now more than ever we need research to better treat and diagnose
prostate cancer.


Since 1996, the Committee has been instrumental in advancing prostate cancer research by funding the DOD’s Congressionally Directed Medical Research Program (CDMRP) for prostate cancer. Its administrative structure has demonstrated an ability to be flexible
and quickly adjust responses to changing medical research needs and priorities. The PCRP, which compliments larger NIH basic science efforts, is the gold standard in prostate cancer research and an integral weapon in the national fight against prostate cancer.


Unlike the NIH, PCRP has clear priorities each year that target gaps in prostate cancer diagnostics, care, and treatment with an emphasis on meeting the needs of the prostate cancer community.  The programmatic review of all proposals ensures that the government
is not spending scarce dollars on duplicative research. This structure works.  In the last nine years, the PCRP has produced three new treatments for metastatic prostate cancer and one new advanced diagnostic.


Not only is the PCRP effective, it is military relevant. Prostate cancer is the most frequently diagnosed cancer among male veterans.  Active duty men have an incidence rate that is twice that of the general population.  Between 2005 and 2014, prostate cancer
accounted for 11.7 percent of cancer diagnoses in active duty men. In addition, it is well known that cancer diagnoses among service members as well as their families have a negative impact on psychological health and military readiness.


For these reasons, we request a FY2021 appropriation of $110 million for the PCRP within the CDMRP, which is equal to the FY2020 level. Researchers will use this funding to: develop treatments that improve outcomes for men with lethal prostate cancer; reduce
lethal prostate cancer in African Americans, Veterans, and other high-risk populations; define the biology of lethal prostate cancer to reduce death; and improve the quality of life for survivors of prostate cancer.


Please join us in making prostate cancer research, awareness and early detection a national health care priority by ensuring that adequate resources are available for the DOD PCRP. We recognize the difficult task ahead of your subcommittee in setting priorities
among the many needs of our nation but we greatly appreciate your consideration of this request.




Related Legislative Issues

Selected legislative information: Appropriations, Armed Services, HealthCare, Veterans

icon eDC logo e-Dear Colleague version 2.0
e-Dear Colleagues are intended for internal House use only.